Enzyme Inhibition
Enzyme Inhibition & DDI Studies
Evaluate CYP450 and UGT Inhibition to Predict Drug–Drug Interaction Risk
Enzyme inhibition studies are critical for predicting pharmacokinetics because inhibition of these enzymes may result in decreased clearance of the drug or another metabolized compound.
As part of our comprehensive portfolio of ADME-Tox research services we provide the following enzyme inhibition studies. Our study designs comply with current regulatory guidance for enzyme inhibition studies.
CYP450 Inhibition
CYP450 inhibition studies predict if exposure to a test article will result in decreased synthesis and concentration of CYP450 enzymes.
CYP450 Inhibition
CYP450 inhibition studies predict if exposure to a test article will result in decreased synthesis and concentration of CYP450 enzymes.
Fluorescence CYP-Inhibition
We offer fluorescent based cyp-inhibition screening services to determine CYP inhibition potential of novel compounds, using BACTOSOMES™ as the enzyme source.
UGT Inhibition
We offer definitive In vitro UDP-glucuronosyltransferase (UGT) Inhibition Studies to predict if drug candidates inhibit cytochrome P450 enzymes.
Automation and Analysis
Enzyme inhibition studies are implemented in our state-of-the-art laboratory where we offer:
Tecan liquid handling automation systems
LC-MS/MS analysis
High throughput autosamplers
Deuterated metabolites used as internal standards (all CYPs and most UGTs)
Automated data retrieval and processing
Comprehensive reports